概述

  • 产品名称Olomoucine
  • 描述
    ATP-competitive CDK inhibitor
  • 生物学描述ATP-competitive CDK inhibitor (IC50 values are 7 (CDC2/cyclin B), 7 (CDK2/cyclin A), 7 (CDK2/cyclin E), 3 (CDK/p35 kinase) and 25 μM (ERK1/p44 MAPK)). Inhibits cell cycle progression in vitro and in vivo.
  • 纯度> 98%

性能

    Olomoucine (ab120938)参考文献

    This product has been referenced in:
    • Zhu Z  et al. Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia 55:546-58 (2007). Read more (PubMed: 17243097) »
    • Raynaud FI  et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11:4875-87 (2005). Read more (PubMed: 16000586) »
    • Veselý J  et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224:771-86 (1994). Read more (PubMed: 7925396) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120938.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"